David Healy1, Joanna Le Noury1, Dee Mangin2. 1. North Wales Department of Psychological Medicine, Bangor, Wales, UK. 2. David Braley and Nancy Gordon Chair of Family Medicine, Department of Family Medicine, McMaster University, Hamilton, ON, Canada.
Abstract
OBJECTIVE: A petition to the European Medicines Agency provided an opportunity to collect reports of a specific adverse event from patients and healthcare professionals, along with details of clinicians' attitudes when asked to endorse patient reports. METHODS: We approached a cohort of patients reporting post-SSRI sexual dysfunction (PSSD) to an adverse event reporting website, RxISK.org. The responses of patients on their interactions with healthcare professionals were subject to a qualitative analysis. RESULTS: A total of 62 participants from 23 countries provided details of their experiences. While some had received support and validation of their condition, many described a number of difficulties including a lack of awareness or knowledge about PSSD, not being listened to, receiving unsympathetic or inappropriate responses, and a refusal to engage with the published medical literature. CONCLUSIONS: Healthcare professionals are nervous about or reluctant to engage with novel problems on a treatment. This is not widely appreciated and the reasons for this concern are not understood.
OBJECTIVE: A petition to the European Medicines Agency provided an opportunity to collect reports of a specific adverse event from patients and healthcare professionals, along with details of clinicians' attitudes when asked to endorse patient reports. METHODS: We approached a cohort of patients reporting post-SSRI sexual dysfunction (PSSD) to an adverse event reporting website, RxISK.org. The responses of patients on their interactions with healthcare professionals were subject to a qualitative analysis. RESULTS: A total of 62 participants from 23 countries provided details of their experiences. While some had received support and validation of their condition, many described a number of difficulties including a lack of awareness or knowledge about PSSD, not being listened to, receiving unsympathetic or inappropriate responses, and a refusal to engage with the published medical literature. CONCLUSIONS: Healthcare professionals are nervous about or reluctant to engage with novel problems on a treatment. This is not widely appreciated and the reasons for this concern are not understood.
Authors: A Sansone; A Aversa; G Corona; A D Fisher; A M Isidori; S La Vignera; E Limoncin; M Maggi; M Merico; E A Jannini Journal: J Endocrinol Invest Date: 2020-10-30 Impact factor: 4.256
Authors: David Healy; Audrey Bahrick; Maarten Bak; Angelo Barbato; Rocco Salvatore Calabrò; Barbara M Chubak; Fiammetta Cosci; Antonei B Csoka; Barbara D'Avanzo; Silvia Diviccaro; Silvia Giatti; Irwin Goldstein; Heiko Graf; Wayne J G Hellstrom; Michael S Irwig; Emmanuele A Jannini; Paddy K C Janssen; Mohit Khera; Manoj Therayil Kumar; Joanna Le Noury; Michał Lew-Starowicz; David E J Linden; Celine Lüning; Dee Mangin; Roberto Cosimo Melcangi; Omar Walid Muquebil Ali Al Shaban Rodríguez; Jalesh N Panicker; Arianna Patacchini; Amy M Pearlman; Caroline F Pukall; Sanjana Raj; Yacov Reisman; Rachel S Rubin; Rudy Schreiber; Stuart Shipko; Barbora Vašečková; Ahad Waraich Journal: Int J Risk Saf Med Date: 2022